These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 34949299)

  • 41. Antiretroviral therapy in children--increased benefit from increased complexity.
    Cotton MF
    S Afr Med J; 2000 Oct; 90(10):985-8. PubMed ID: 11081099
    [No Abstract]   [Full Text] [Related]  

  • 42. Patient perspectives of pharmacists prescribing HIV pre-exposure prophylaxis: A survey of patients receiving antiretroviral therapy.
    Lutz S; Heberling M; Goodlet KJ
    J Am Pharm Assoc (2003); 2021; 61(2):e75-e79. PubMed ID: 33069595
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action.
    Jarvis JN; Lawn SD; Wood R; Harrison TS
    Clin Infect Dis; 2010 Dec; 51(12):1463-5. PubMed ID: 21082878
    [No Abstract]   [Full Text] [Related]  

  • 44. A Case Study of an Effective and Sustainable Antiretroviral Therapy Program in Rural South Africa.
    Le Roux KW; Davis EC; Gaunt CB; Young C; Koussa M; Harris C; Rotheram-Borus MJ
    AIDS Patient Care STDS; 2019 Nov; 33(11):466-472. PubMed ID: 31682167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population-level associations between antiretroviral therapy scale-up and all-cause mortality in South Africa.
    Larson E; Bendavid E; Tuoane-Nkhasi M; Mbengashe T; Goldman T; Wilson M; Klausner JD
    Int J STD AIDS; 2014 Aug; 25(9):636-42. PubMed ID: 24352117
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.
    Abbas UL; Glaubius R; Mubayi A; Hood G; Mellors JW
    J Infect Dis; 2013 Jul; 208(2):224-34. PubMed ID: 23570850
    [TBL] [Abstract][Full Text] [Related]  

  • 47. "Now here come the pills that are going to save your life": pharmacists' discussions of antiretroviral drugs in a context of life and death.
    Watermeyer J
    AIDS Care; 2011 Jul; 23(7):807-13. PubMed ID: 21400313
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared.
    Keiser O; Orrell C; Egger M; Wood R; Brinkhof MW; Furrer H; van Cutsem G; Ledergerber B; Boulle A;
    PLoS Med; 2008 Jul; 5(7):e148. PubMed ID: 18613745
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Study of the usefulness of pharmacist consultations for patients on antiretroviral regimens].
    Guerrault MN; Leclerc C; Langevin S; Merian-Brosse L; Brossard D; Welker Y
    Presse Med; 2005 Nov; 34(20 Pt 2):1563-70. PubMed ID: 16314815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Steady growth in antiretroviral treatment provision by disease management and community treatment programmes.
    Johnson LF; McLeod HD
    S Afr Med J; 2007 May; 97(5):358-9. PubMed ID: 17599217
    [No Abstract]   [Full Text] [Related]  

  • 51. Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should.
    Bassett IV; Regan S; Chetty S; Giddy J; Uhler LM; Holst H; Ross D; Katz JN; Walensky RP; Freedberg KA; Losina E
    AIDS; 2010 Jan; 24 Suppl 1(Suppl 1):S37-44. PubMed ID: 20023438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Study finds intensive coaching improves antiretroviral therapy adherence.
    Said DA; Provost GP
    Am J Health Syst Pharm; 2002 Sep; 59(17):1600-1. PubMed ID: 12224338
    [No Abstract]   [Full Text] [Related]  

  • 53. Can highly active antiretroviral therapy reduce the spread of HIV?: A study in a township of South Africa.
    Auvert B; Males S; Puren A; Taljaard D; Caraël M; Williams B
    J Acquir Immune Defic Syndr; 2004 May; 36(1):613-21. PubMed ID: 15097305
    [TBL] [Abstract][Full Text] [Related]  

  • 54. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A pharmacovigilance study of adults on highly active antiretroviral therapy, South Africa: 2007 - 2011.
    Dube NM; Summers R; Tint KS; Mayayise G
    Pan Afr Med J; 2012; 11():39. PubMed ID: 22593775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme.
    Jarvis JN; Meintjes G; Wood R; Harrison TS
    AIDS; 2010 May; 24(8):1233-5. PubMed ID: 20421745
    [No Abstract]   [Full Text] [Related]  

  • 57. Medicines Control Council and registration backlog of antiretrovirals.
    Gosling J
    S Afr Med J; 2007 Mar; 97(3):148, 150. PubMed ID: 17440652
    [No Abstract]   [Full Text] [Related]  

  • 58. Cabinet rules that South Africans must be given antiretrovirals.
    Sidley P
    BMJ; 2003 Aug; 327(7411):357. PubMed ID: 12919970
    [No Abstract]   [Full Text] [Related]  

  • 59. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
    BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Task shifting for antiretroviral treatment delivery in sub-Saharan Africa: not a panacea.
    Philips M; Zachariah R; Venis S
    Lancet; 2008 Feb; 371(9613):682-684. PubMed ID: 18295026
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.